MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-238

  1. 142 Posts.
    lightbulb Created with Sketch. 16
    Just updating my post

    I checked back to the ODAC submission (Table 40 - page 108 of 127)

    RemL had a 100 day survival rate of 74.1% against a Magic Database 57.1%.

    RemL 100 Day Non-relapse Mortality of 18.5% against a Magic Database 39.3%.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.